Completed NA INTERVENTIONAL NCT00002253
A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either Responders or Non-Responders in a Prior Placebo-Controlled Double-Blind Sandostatin Study.
Sponsor: Sandoz
Conditions
Diarrhea HIV Infections
Interventions
Octreotide
Updated 5 times since 2017 Last updated: Jun 23, 2005
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This NA trial investigates Diarrhea and HIV Infections and is currently completed. Sandoz leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Sandoz
Data source: NIH AIDS Clinical Trials Information Service
For direct contact, visit the study record on ClinicalTrials.gov .